The field of neuromodulation continues to evolve rapidly, and new findings are shaping what the future of interventional psychiatry could look like. In a recent randomized clinical trial examining accelerated TMS for depression, researchers explored whether multiple daily sessions could deliver outcomes comparable to traditional treatment schedules. The study, published in Brain Stimulation, highlights emerging possibilities for more time-efficient care within the broader landscape of advances in interventional psychiatry.
Major depressive disorder affects millions of people worldwide, and a significant portion of patients do not respond adequately to medication or psychotherapy. Transcranial magnetic stimulation has become an important noninvasive option for treatment-resistant depression, but conventional treatment schedules still present logistical challenges for many patients.
Why Traditional TMS Treatment Schedules Can Be Difficult For Patients
Standard FDA-cleared TMS protocols typically require patients to attend one treatment session per day, five days per week, over four to six weeks. Although effective, this schedule can be difficult for individuals balancing work, family responsibilities, transportation challenges, or long travel distances to clinics.
These practical barriers often delay or prevent patients from accessing neuromodulation therapies. As a result, researchers have been exploring accelerated treatment protocols that condense multiple sessions into a shorter time frame while maintaining clinical effectiveness.
Accelerated approaches aim to reduce the number of clinic visits while delivering the same or greater therapeutic exposure.
Testing Accelerated TMS For Depression In A Multisite Randomized Trial
To investigate this approach, researchers conducted a multicenter randomized noninferiority trial comparing an accelerated intermittent theta burst stimulation protocol with the standard high frequency H1-coil TMS protocol.
The trial enrolled 104 adults with moderate to severe major depressive disorder who had not responded adequately to antidepressant medications. Participants were randomly assigned to one of two treatment groups.
The accelerated protocol delivered five TMS sessions per day across six treatment days within a two week period. Each session used intermittent theta burst stimulation parameters delivered through the H1 coil, targeting the bilateral prefrontal cortex.
By contrast, the standard protocol followed the conventional once-daily treatment schedule over several weeks.
The primary outcome measured change in depression severity using the Hamilton Depression Rating Scale over a six week period.
Accelerated TMS For Depression Produced Comparable Clinical Outcomes
Both treatment groups experienced substantial reductions in depressive symptoms. Patients receiving accelerated TMS improved by an average of roughly 19 points on the depression rating scale, which was statistically comparable to improvements seen with the standard protocol.
Importantly, the accelerated treatment met the predefined criteria for noninferiority. In other words, compressing the treatment schedule did not reduce overall effectiveness.
Response and remission rates were also strikingly high in both groups. Approximately 88 percent of patients achieved clinical response, while remission occurred in roughly 78 percent of the accelerated treatment group and 87 percent of the standard protocol group.
These results suggest that condensed treatment schedules can achieve similar clinical outcomes to traditional TMS delivery.
Faster Symptom Improvement May Be One Of The Key Advantages
One notable difference between the treatment approaches was the speed of improvement.
Patients receiving accelerated TMS reached remission significantly sooner than those undergoing standard daily sessions. Median time to remission was approximately 21 days in the accelerated group compared with about 28 days in the traditional protocol.
Earlier symptom improvement may have meaningful clinical implications. For individuals experiencing severe depressive symptoms, shortening the time to relief can substantially improve functioning, quality of life, and treatment adherence.
Accelerated schedules may also help clinics treat more patients while reducing the number of weeks individuals must commit to therapy.
Understanding The Neuroplasticity Mechanism Behind Accelerated Protocols
Accelerated stimulation protocols may influence neuroplasticity in ways that differ from traditional dosing schedules.
Theta burst stimulation delivers bursts of high frequency pulses that mimic patterns observed in natural brain activity associated with learning and synaptic plasticity. Delivering multiple sessions within a shorter window may amplify neuroplastic changes within prefrontal mood circuits.
The H1 coil used in this study is designed to stimulate broader and deeper regions of the prefrontal cortex compared with conventional figure-eight coils. This expanded stimulation field may contribute to the robust response rates observed in both treatment arms.
Researchers also noted that the continuation phase of treatment may help consolidate therapeutic effects following the intensive initial stimulation period.
What This Study Means For The Future Of TMS Treatment
Accelerated TMS protocols could significantly improve access to neuromodulation therapies if they prove scalable in real-world clinical settings.
Shorter treatment schedules may reduce barriers for patients who cannot attend daily sessions for several weeks. Clinics may also benefit from more flexible scheduling and the ability to treat larger patient populations.
However, several questions remain. Long term durability of accelerated protocols still requires additional investigation, and future studies may explore how biomarkers, brain imaging, or symptom clusters can guide personalized dosing schedules.
As research continues, accelerated TMS for depression may represent an important step toward more efficient and patient-centered neuromodulation treatments.
Citations
Hanlon CA et al. Accelerated TMS with the H1-coil for depression: A multisite randomized noninferiority trial. Brain Stimulation. https://doi.org/10.1016/j.brs.2026.103050
Rush AJ et al. Acute and longer term outcomes in depressed outpatients requiring multiple treatment steps. American Journal of Psychiatry. https://doi.org/10.1176/ajp.2006.163.11.1905
Explore more at https://www.interventionalpsychiatry.org/